BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11029605)

  • 1. Serum concentration of 5-S-cysteinyldopa in patients with melanoma.
    Bánfalvi T; Gilde K; Boldizsár M; Fejös Z; Horváth B; Liszkay G; Beczássy E; Kremmer T
    Eur J Clin Invest; 2000 Oct; 30(10):900-4. PubMed ID: 11029605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression.
    Bánfalvi T; Gilde K; Boldizsár M; Kremmer T; Ottó S
    Pathol Oncol Res; 1999; 5(3):218-22. PubMed ID: 10491021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience.
    Wakamatsu K; Kageshita T; Furue M; Hatta N; Kiyohara Y; Nakayama J; Ono T; Saida T; Takata M; Tsuchida T; Uhara H; Yamamoto A; Yamazaki N; Naito A; Ito S
    Melanoma Res; 2002 Jun; 12(3):245-53. PubMed ID: 12140381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of 5-S-cysteinyldopa monitoring in patients with malignant melanoma.
    Bánfalvi T; Gilde K; Boldizsár M; Kremmer T
    Neoplasma; 2002; 49(2):121-5. PubMed ID: 12088105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.
    Bánfalvi T; Boldizsár M; Gergye M; Gilde K; Kremmer T; Ottó S
    Pathol Oncol Res; 2002; 8(3):183-7. PubMed ID: 12515998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa.
    Matsushita Y; Hatta N; Wakamatsu K; Takehara K; Ito S; Takata M
    Melanoma Res; 2002 Aug; 12(4):319-23. PubMed ID: 12170180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
    Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
    Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients.
    Wakamatsu K; Yokochi M; Naito A; Kageshita T; Ito S
    Melanoma Res; 2003 Aug; 13(4):357-63. PubMed ID: 12883361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma.
    Bánfalvi T; Gilde K; Gergye M; Boldizsár M; Kremmer T; Ottó S
    Eur J Cancer; 2003 Jan; 39(2):164-9. PubMed ID: 12509947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression.
    Hirai S; Kageshita T; Kimura T; Tsujisaki M; Imai K; Wakamatsu K; Ito S; Ono T
    Melanoma Res; 1997 Feb; 7(1):58-62. PubMed ID: 9067966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of melanin-related metabolites as markers of melanoma progression.
    Horikoshi T; Ito S; Wakamatsu K; Onodera H; Eguchi H
    Cancer; 1994 Feb; 73(3):629-36. PubMed ID: 8299084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.
    Kärnell R; von Schoultz E; Hansson LO; Nilsson B; Arstrand K; Kågedal B
    Melanoma Res; 1997 Oct; 7(5):393-9. PubMed ID: 9429222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma.
    Hasegawa M; Takata M; Hatta N; Wakamatsu K; Ito S; Takehara K
    Melanoma Res; 1997 Jun; 7(3):243-51. PubMed ID: 9195564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating melanoma cells as a potential biomarker to detect metastasis and evaluate prognosis.
    Hida T; Yoneta A; Wakamatsu K; Yanagisawa K; Ishii-Osai Y; Kan Y; Kato J; Yamashita T
    Australas J Dermatol; 2016 May; 57(2):145-9. PubMed ID: 26931184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum 5-S-cysteinyldopa (5-S-CD) as a marker of melanoma progression.
    Horikoshi T; Ito S
    J Dermatol; 1992 Nov; 19(11):809-13. PubMed ID: 1293168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects.
    Peterson LL; Woodward WR; Fletcher WS; Palmquist M; Tucker MA; Ilias A
    J Am Acad Dermatol; 1988 Sep; 19(3):509-15. PubMed ID: 3139723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum 5-S-cysteinyldopa behavior in the early phase of nivolumab treatment of 12 melanoma patients.
    Omodaka T; Minagawa A; Uhara H; Wakamatsu K; Koizumi T; Yokokawa Y; Koga H; Okuyama R
    J Dermatol; 2018 Nov; 45(11):1340-1344. PubMed ID: 30144152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of 5-S-cysteinyldopa testing using a new and optimized detection system as a tumour marker for malignant melanoma.
    Meyer T; Hauschild A; Kromminga A; Hartleb J; Arndt R; Christophers E; Stockfleth E
    Melanoma Res; 2002 Oct; 12(5):471-7. PubMed ID: 12394189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of primary melanoma of the lung monitored by 5-S-cysteinyldopa levels.
    Shikuma K; Omasa M; Yutaka Y; Okuda M; Taki T
    Ann Thorac Surg; 2009 Apr; 87(4):1264-6. PubMed ID: 19324166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normal values of urinary excretion and serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid, biochemical markers of melanoma progression.
    Wakamatsu K; Ito S; Horikoshi T
    Melanoma Res; 1991; 1(2):141-7. PubMed ID: 1823626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.